08 August 2014 : Original article
Thiazolidinedione Therapy Versus Lifestyle Recommendation in the Treatment of Post-Liver Transplant Graft Steatosis
Fredrik ÅbergABCDEF, Virve KoljonenABCDEF, Katriina NikkiläABDEF, Sonja BoydBCDE, Johanna ArolaABDE, Helena IsoniemiADEDOI: 10.12659/AOT.890664
Ann Transplant 2014; 19:389-396
Abstract
BACKGROUND: Few studies have investigated intervention therapy to reduce steatosis in the liver allograft post-transplantation.
MATERIAL AND METHODS: We compared the use of thiazolidinedione (TZD) therapy (rosiglitazone or pioglitazone) with intensified lifestyle recommendation retrospectively in 22 liver transplant patients with ³10% macrovesicular steatosis on biopsies obtained ≥9 months post-transplant.
RESULTS: The 10 patients receiving TZD therapy and 12 receiving intensified lifestyle recommendation were comparable with respect to age, sex, disease etiology, immunosuppression regimen, and diabetes, but patients receiving TZD therapy were less overweight at start of treatment. From baseline to last biopsy, patients subject to lifestyle recommendation (mean follow-up 14 months) lost an average of 3.5 kg body weight, whereas TZD patients (mean follow-up 9 months) gained an average of 4.1 kg. Hepatic macrovesicular steatosis decreased from 63% to 31% among TZD-treated patients (p=0.005), and from 47% to 33% among those subject to lifestyle recommendation (p=0.17). Absolute and percentage change in body weight correlated with the decreased steatosis in the lifestyle group (rho=0.84 and rho=0.87, respectively, p=0.001–0.002), but not in the TZD group (rho=–0.04, p=0.92). Five patients in the TZD group stopped the medication after an average 14 months of therapy.
CONCLUSIONS: Liver graft steatosis can be reduced through weight loss or TZD treatment, but considering the risks and benefits, we advocate lifestyle recommendation as the first-line intervention.
Keywords: Diet, Reducing, Fatty Liver, Life Style, Liver Transplantation, Thiazolidinediones
In Press
Original article
The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival Afte...Ann Transplant In Press; DOI: 10.12659/AOT.945249
Original article
Biopsychosocial Effects of Donor Traits on Heart Transplant RecipientsAnn Transplant In Press; DOI:
Clinical Research
Ten-Year Retrospective Analysis of Continuous Renal Replacement Therapy in Burn Patients: Impact on Surviva...Ann Transplant In Press; DOI:
Original article
Factors Influencing Stress Disorders in Intensive Care Unit (ICU) Patients After Liver Transplantation: A C...Ann Transplant In Press; DOI: 10.12659/AOT.944320
Most Viewed Current Articles
05 Apr 2022 : Original article 13,099
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,248
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,598
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,261
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860